Skip to main content

Table 5 Cox proportional-hazards regression: univariate and multivariate analyses

From: A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

A Univariate Analysis Multivariate Analysis
VARIABLE HR (95% CI); p - value HR (95% CI); p - value
  Time to Treatment Failure
BMI
≥ 25 vs < 25
0.54 (0.45–0.66); p < 0.0001 0.74 (0.56–0.97); p = 0.0330
  Progression Free Survival
BMI
≥ 25 vs < 25
0.49 (0.40–0.59); p < 0.0001 0.77 (0.58–1.01); p = 0.0668
  Overall Survival
BMI
≥ 25 vs < 25
0.38 (0.31–0.48); p < 0.0001 0.59 (0.43–0.81); p = 0.0013
B Univariate Analysis Multiavariate Analysis
VARIABLE HR (95% CI); p - value HR (95% CI); p - value
  Time to Treatment Failure
BMI
≥ 25 vs < 25
0.45 (0.35–0.61); p < 0.0001 0.51 (0.32–0.80); p = 0.0037
  Progression Free Survival
BMI
≥ 25 vs < 25
0.41 (0.31–0.56); p < 0.0001 0.56 (0.35–0.88); p = 0.0132
  Overall Survival
BMI
≥ 25 vs < 25
0.25 (0.17–0.36); p < 0.0001 0.27 (0.15–0.48); p < 0.0001
  1. (A) male patients (B) female patients. The used covariates (not shown) were: weight (continuous), irAEs of any grade, primary tumors, line of treatment, ECOG-PS, number of metastatic sites